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Abstract
Background: The retinoblastoma product (RB1) is frequently deregulated in various types of tumors by mutation,
deletion, or inactivation through association with viral oncoproteins. The functional loss of RB1 is recognized to be
one of the hallmarks that differentiate cancer cells from normal cells. Many researchers are attempting to develop
anti-tumor agents that are preferentially effective against RB1-negative tumors. However, to identify patients with
RB1-negative cancers, it is imperative to develop predictive biomarkers to classify RB1-positive and -negative tumors.
Results: Expression profiling of 30 cancer cell lines composed of 16 RB1-positive and 14 RB1-negative cancers was
performed to find genes that are differentially expressed between the two groups, resulting in the identification of
an RB1 signature with 194 genes. Among them, critical RB1 pathway components CDKN2A and CCND1 were
included. We found that microarray data of the expression ratio of CCND1 and CDKN2A clearly distinguished the
RB1 status of 30 cells lines. Measurement of the CCND1/CDKN2A mRNA expression ratio in additional cell lines by
RT-PCR accurately predicted RB1 status (12/12 cells lines). The expression of CCND1/CDKN2A also correlated with
RB1 status in xenograft tumors in vivo. Lastly, a CCND1/CDKN2A assay with clinical samples showed that uterine
cervical and small cell lung cancers known to have a high prevalence of RB1-decifiency were predicted to be 100%
RB1-negative, while uterine endometrial or gastric cancers were predicted to be 5-22% negative. All clinically
normal tissues were 100% RB1-positive.
Conclusions: We report here that the CCND1/CDKN2A mRNA expression ratio predicts the RB1 status of cell lines
in vitro and xenograft tumors and clinical tumor samples in vivo. Given the high predictive accuracy and
quantitative nature of the CCND1/CDKN2A expression assay, the assay could be utilized to stratify patients for anti-
tumor agents with preferential effects on either RB1-positive or -negative tumors.
Background
Retinoblastoma protein (RB1) is a crucial regulator of
appropriate cell cycle progression, including G1 to S
and G2 to M phase transitions [1,2]. The activity of RB1
is mainly regulated by the upstream CDKN2A/CCND1
pathway [3-5]. Anti-proliferative stresses including DNA
damage, therapeutic agents, and anti-mitogens increase
the expression of CDKN2A followed by the dissociation
of CDK4 or CDK6/CCND1 complexes. The inactivation
of CDKs/CCND1 leads to the hypophosphorylation of
RB1, resulting in the transcriptional repression of E2F/
DP regulatory genes that contributes to the progression
of cell cycles including mini-chromosome maintenance
(MCM) genes [6], A/D/E-type Cyclins [7-9], and CDC6
[10]. In accordance with the important role of RB1 as a
cell cycle regulator, RB1 deregulation is frequently
observed in multiple types of cancers [11]. Functional
loss of RB1 causes accelerated E2F1 mediated transacti-
vation, followed by uncontrolled cell cycle progression.
In small cell lung cancer (SCLC), for example, the pre-
valence of RB1 loss is more than 90% [12,13], while RB1
function in cervical cancer is suppressed by directly
associating with HPV-E7 oncoprotein at a frequency of
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function has been reported in several other types of
cancers such as bladder, prostate cancers, and mela-
noma [16-18]. The RB1 loss is caused by several mole-
cular events such as point mutations, deletion, or
inactivation through associating viral proteins [19]. In
addition, genetic alteration or aberrant expression in
upstream molecules also results in dysfunction of RB1.
Accumulating evidence has shown that hypermethyla-
tion in the promoter region of CDKN2A or overexpres-
sion of CCND1, which results in RB1 dysfunction,
frequently occurs in various types of cancers [11].
Therefore, deregulation in the RB1 pathway is recog-
nized to be a hallmark of tumorigenesis.
Since most current standard-of-care anti-tumor drugs
are cytotoxic agents, they do not possess selective killing
effects on tumors compared with normal proliferating
cells. Development of drugs which preferentially exert
anti-tumor effects in tumors harboring specific deregula-
tion in tumor-related genes is eagerly anticipated [20].
Given the different status of RB1 between tumor and
normal cells, several studies have attempted to develop
anti-tumor agents which selectively inhibit growth of
tumors with dysfunctional RB1 [20-24]. The silencing of
ECT2, which is a GTP exchanging factor involved in
cytokinesis, is effective in RB1-negative cells when
examined with RB1-positive and -negative isogenic cell
lines in the presence of DNA damage [21]. It has also
been shown that inhibition of Aurora B can induce
increased apoptosis in RB1-deficient cells [22]. The
response to standard chemotherapeutics is also affected
by the status of RB1. RB1-negative cancers are more
s e n s i t i v et os o m eD N A - d a m a g i n ga g e n t ss u c ha s
5-Fluorouracil [23], doxorubicin [24], and ionizing radia-
tion [25], although the detailed mechanism for the RB1-
negative selective effect remains unresolved. Tamoxifen
is more effective against RB-positive breast cancers than
-negative ones in vitro [26]. This knowledge might be
integrated in future clinical trials to develop RB1-status
dependent anti-tumor agents, and potentially increase
the therapeutic window of those agents.
In order to utilize anti-tumor agents whose effect is dif-
ferent between RB1-positive and -negative cancers, the
development of a predictive biomarker that discriminates
the status of RB1 in cells is essential. Conventionally, the
protein expression level of RB1 as measured by immuno-
histochemistry (IHC) has been used to estimate the preva-
lence of RB1 deficiency in various tumor types. Direct
measurement of RB1 by IHC has generated vast amounts
of information on RB1 deficiency in many types of cancers;
however, it has several drawbacks as a biomarker to predict
RB1 status. First, IHC for RB1 detects limited types of RB1
dysfunction, although RB1 loss can be caused by muta-
tions, deletion, or association with viral proteins [11].
For instance, IHC for RB1 would be positive in tumors
infected with HPV-virus expressing E7 oncoprotein,
although RB1 is functionally lost [14]. Second, IHC is
semi-quantitative, and comparisons of RB1 loss frequency
among different studies are somewhat difficult [27]. This
also makes it difficult to establish a threshold to distinguish
RB-positive and -negative tumors that would guide investi-
gators to determine whether the tumors be treated with
anti-tumor agents whose effects are dependent on RB1 sta-
tus [28]. Lastly, IHC methods mandate a relatively large
amount of biopsy samples. When a predictive marker is
used clinically, a minimally invasive biopsy is highly prefer-
able from the patient’s point of view. Therefore, the devel-
opment of a novel RB1 predictive biomarker that
overcomes these drawbacks would be useful for patient
stratification by complementing or replacing the current
direct RB1 protein measurement.
In the present study, we compared expression profiling
of RB1-positive and -negative cell lines among 30 cancer
cell lines, and identified a gene signature that was differ-
entially expressed between the two groups. In the gene
signature, CDKN2A and CCND1, which are the impor-
tant nodal proteins in the RB1 pathway, were included.
We found that the expression ratio of CCND1 to
CDKN2A clearly classified RB1-positive and -negative
cancer lines, the predictive accuracy of which was super-
ior to that of individual CDKN2A or CCND1, respec-
tively. The CCND1/CDKN2A ratio could also classify the
RB1 status of xenograft tumors in vivo. Finally, CCND1/
CDKN2A expressions were measured in formalin fixed
paraffin embedded (FFPE) samples of clinical tumor and
normal tissues. We found that uterine cervical and small
cell lung cancers were predicted to be RB-negative at
high prevalence, while most uterine endometrial and sto-
mach cancers were predicted to be RB1-positive by the
CCND1/CDKN2A assay.
Results
Identification of a gene signature to classify RB1 status
by microarray analysis
We collected a panel of cancer cell lines to be used for
the identification of a gene signature that discriminates
between RB1-positive and -negative cell lines (Table 1).
We first selected 11 cell lines, the RB1 status of which
has been previously reported as negative. Other than
the HeLa cell line, all the cell lines possess genetic
alterations such as frame shifts or termination muta-
tions, such that the function of RB1 is completely
lost in 10 of the cell lines. Since the HeLa cell line
expresses E7 proteins from papilloma virus, RB1 func-
tion is known to be dysfunctional. The RB1 functional
status of the 11 cell lines and additional 19 cell lines
was determined by a cellular assay which measures the
activity of E2F-regulatory reporter gene in response to
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Page 2 of 11CDKN2A induction [21]. The cell lines were trans-
fected with both the CDKN2A gene and the E2F regu-
latory reporter gene. In RB1-positive cells, the induced
CDKN2A protein inhibits endogenous CDKs, leading
to the activation of RB1 proteins, which is followed by
the inhibition of E2F-mediated transcription. In RB1-
negative cells, the E2F reporter gene does not respond
to CDKN2A induction. With the cellular RB1 func-
tional assay, 16 cell lines were identified as RB1-
positive because they showed significant inhibition of
the E2F reporter gene upon induction of the CDKN2A
protein, while the other three cell lines were character-
ized as RB1-negative (Additional file 1A). In total, 16
RB1-positive and 14 RB1-negative cell lines were used
for the identification of an RB1 classifier (Table 1).
Next, to find genes which are differentially expressed
between the RB1-positive and -negative cell lines,
mRNA expression profiles were carried out with an
Agilent oligonucleotide microarray. All microarray
hybridization was performed with Human Universal
Reference RNAs to enable comparative analysis among
the cell lines. We selected genes whose standard devia-
tion of expressional log10 ratio in all 30 cell lines was
greater than or equal to 0.1. We further extracted genes
whose p-value of Pearson correlation coefficiency
between expressional log10 ratio and RB1 status was less
than or equal to 0.001. As a result, 194 genes were
selected as an RB1 status signature. When hierarchical
2 D clustering was performed with the genes and the
30 cell lines, the 16 RB1-positive and 14 RB1-negative
cell lines were accurately classified into the two groups
(Figure 1), suggesting that the gene signature could be a
tool to determine the status of RB1. The signature
included RB1 itself and its expression in the 30 cell
lines are shown in Additional file 1B. When a hypergeo-
metric test for gene enrichment was conducted against
the RB1 signature gene, the examination showed that
the genes whose function is related to the G1-S phases
of cell cycle were significantly condensed in up-regulated
genes (G1 phase: 5.9 × 10
-3; S phase: 4.2 × 10
-2). The
results of the enrichment test were in accordance with the
function of RB1 as a cell cycle regulator through G1 to S
phase transition.
Expression ratio of CCND1 to CDKN2A predicts RB1 status
An RB1 classifier would be useful as a predictive bio-
marker for some anti-tumor agents whose efficacy
depends on RB1 status. In order to use an RB1 classi-
fier in clinical trials, it is highly preferable to reduce
the number of genes without affecting the prediction
accuracy. Within the RB1 gene signature composed of
194 genes, we found that CDKN2A and CCND1,
which are key regulators in the RB1 pathway, were
included. When we compared the RB1 status with
either CDKN2A or CCND1 expression, both of them
were highly correlated (p < 0.01). This is in accordance
with previous reports that RB1 status is inversely cor-
related with CDKN2A [13,14]. However, the expression
level of either CDKN2A or CCND1 alone did not
accurately classify the 30 RB1-positive or -negative cell
l i n e st h a tw e r eu s e dt of i n dt h eR B 1g e n es i g n a t u r e
(Figure 2A and 2B). We next explored whether a com-
bination of CCND1 and CDKN2A expression data
would predict RB1 status. In Figure 2C, the correlation
of CDKN2A and CCND1 expressions and RB1 status
is shown. We found that the expression ratio of
CCND1 and CDKN2A precisely classified the RB1-
positive and -negative cell lines.
Table 1 RB1 status of 30 cancer cell lines used for gene
expression
Cell line Tissue
type
RB1 genetic status RB1 functional
status
T-24 bladder wild-type +
U-2-OS bone wild-type +
SF268 CNS wild-type +
DLD-1 colon NA +
HCT-116 colon wild-type +
Hep G2 liver NA +
NCI-H460 NSCLC wild-type +
A549 NSCLC wild-type +
UACC-62 melanoma wild-type +
MDAH-2774 ovary NA +
PANC-1 pancreas NA +
SU.86.86 pancreas NA +
NCI-N87 stomach wild-type +
Hs 746T stomach NA +
KATOIII stomach wild-type +
SCC-25 tongue wild-type +
J82 tongue Δ21 2107-2A > G -
HeLa S3 bladder repressed by E7 -
DU-145 cervix stop: K175* -
TCCSUP bladder deletion:
1696_2787del1092
-
MDA-MB-436 breast frame shift: G203fs*8 -
MDA-MB-468 breast deletion:
265_2787del2523
-
SF-539 CNS deletion: T116fs*8 -
HeLa cervix repressed by E7 -
C-33A cervix deletion: 4aa in exon2 -
Lu-135 SCLC frame shift: R661fs*1 -
NCI-H128 SCLC frame shift: R418fs*2 -
NCI-H1417 SCLC stop: Y321* -
NCI-H69 SCLC stop: E748* -
NCI-H596 NSCLC frame shift: R661fs*1 -
*The functional assay which determined the status of RB1 in the present
study is described in Methods and data are shown in Additional file 1.
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classifier
The predictive accuracy of RB1 status by the CCND1/
CDKN2A ratio was examined with the original 30 can-
cer cell lines which were used to develop the RB1 gene
signature as a training set (Figure 2B). We next investi-
gated whether the CCND1/CDKN2A expression ratio
could predict the RB1 status of an additional 10 cell
lines (Figure 3A) in which the RB1 status was unknown,
and with HeLaS3 and H460 cells as controls of
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Figure 1 Identification of a gene expression signature to classify RB1 status. The expression profiles of 16 RB1-positive and 14 RB1-
negative cancer cell lines were analyzed. One hundred and ninety-four genes which were differentially expressed between the two groups were
extracted as described in Materials and Methods. For the selected genes and 30 cell lines, two-dimensional hierarchical clustering was
conducted. Each row represents a cell line. Each column represents a gene. Red, up-regulated genes; green, down-regulated genes.
RB1 (+) cells
RB1 (-) cells
log10 (CCND1) expression
l
o
g
1
0
(
C
D
K
N
2
A
)
 
e
x
p
r
e
s
s
i
o
n
CDKN2A
RB (+) RB (-)
-2.0
-1.5
-1.0
-0.5
0.0
0.5
l
o
g
1
0
(
C
D
K
N
2
A
)
 
e
x
p
r
e
s
s
i
o
n
CCND1
RB (+) RB (-)
-0.8
-0.6
-0.4
-0.2
-0.0
0.2
0.4
0.6
0.8
1.0
l
o
g
1
0
(
C
C
N
D
1
)
 
e
x
p
r
e
s
s
i
o
n
AB
-1.6
-1.4
-1.2
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
0.2
-0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0
C
Figure 2 Expression pattern of CCND1 and CDKN2A in RB-positive and -negative cell lines. Correlation between RB1 status and CDKN2A
(A) or CCND1 (B) expression level derived from microarray data. (C) Relationship between RB1 status and the ratio of CCND1 to CDKN2A
expression derived from microarray data.
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Page 4 of 11RB-negative and -positive cell lines. The functional RB1
status of the 12 cell lines was determined by the
CDKN2A/E2F reporter gene assay, resulting in seven
and five cell lines as RB1-positive and -negative, respec-
tively (Figure 3A). Next, CCND1 and CDKN2A expres-
sions were determined by quantitative RT-PCR. The
expression ratio of CCND1/CDKN2A clearly classified
the RB-positive and -negative groups determined by the
RB1 functional assay (Figure 3B), although RB1 mRNA
expression level were not associated with the functional
RB1 status (Figure 3C). Discriminant analysis with the
CCND1 to CDKN2A expression ratio data generated by
quantitative RT-PCR from the 12 cell lines established
0.404 as the cut-off value of log10 (CCND1/CDKN2A)
ratio to classify RB1 status, which is detailed in Materi-
als and Methods. Within the 12 test cell lines, the
expression ratio of CCND1 to CDKN2A predicted RB1
status with an accuracy of 100%. Next, to examine
whether CCND1 and CDKN2A could be utilized as an
RB1 classifier in vivo, the RB1 status was determined in
xenograft tumor samples. The reasons to study xeno-
graft tumors are: 1) to examine mRNA samples from
formalin fixed paraffin embedded tissues (FFPET), it is
useful to predict RB1 status by the CCND1/CDKN2A
expression assay; 2) to examine whether three-dimen-
sional structures in xenograft tumors do not affect the
expression ratio. To develop xenograft tumors, cancer
cells were inoculated to nude rats, and xenograft tumors
were formed for 1-2 weeks. The developed xenograft
t u m o r sw e r ef i x e di n1 0 %f o r m a l i na n ds t o r e da s
FFPET. We extracted mRNA from the FFPET samples,
and performed quantitative real-time RT-PCR. As
shown in Figure 4, CCND1/CDKN2A expression ratios
determined with mRNA extracted from FFPET were
almost equivalent to those determined from mRNA
extracted from tissue cultures in vitro,a n dp r e d i c t e d
three xenograft tumors as RB1-positive and the other
two as RB1-negative, which was 100% accurate. This
implies that the RB1 classifier using the CCND1/
CDKN2A ratio would apply to FFPET samples in vivo.
We further validated the RB1 classifier with two publicly
available microarray data sets. First, we applied the RB1
classifier to RB1 wild-type and RB1 knockout mouse
osteoblast samples, and CCND1/CDKN2A expression
ratio clearly discriminated the two genotypes (Figure 4B).
Second, expression profiling data of RB1-expressiong and
RB1-deficient paired SAOS-2 cell lines were analyzed.
The CCDN1/CDKN2A were significantly different
between the two isogenic cells (Additional file 2).
Validation of CCND1/CDKN2A expression in clinical
samples
To examine whether the CCND1/CDKN2A expression
ratio predicts RB1 status in clinical tumor samples,
human clinical tumor and normal samples were analyzed
in CCND1/CDKN2A assays. Uterine cervical, endome-
trial, small cell lung, stomach cancers, and their corre-
sponding normal tissues were investigated. RNA was
extracted from FFPET of the clinical samples and sub-
jected to quantitative RT-PCR. As shown in Figure 5, the
CCND1/CDKN2A ratios of all the normal tissues were
significantly higher compared with those of correspond-
ing tumor tissues, indicating that the RB1 status of all the
normal tissues was positive. Cervical cancer and SCLC,
which are known to be the tumor types with a higher
frequency of dysfunctional RB1, showed lower CCND1/
B
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Figure 3 CCND1/CDKN2A expression predicts RB1 status. (A) RB1 status of 12 cell lines determined by RB1 functional assay. Each cell line
was transfected with E2F-regulatory reporter SEAP plasmid with or without the CDKN2A expression vector. The inhibition level of the SEAP
reporter gene activity in response to CDKN2A induction was normalized to luciferase activity. (B) RB1 status of 12 cell lines predicted by the
expression ratio of CCND1/CDKN2A. mRNAs from the 12 cell lines were analyzed with quantitative RT-PCR analysis for CCND1 and CDKN2A. The
threshold of CCND1/CDKN2A to determine RB1 status was established as 0.404 by discriminate analysis. The RB1 statuses determined by CCND1/
CDKN2A coincided with those determined by RB1 function assay. (C) Relative RB1 mRNA expression level in 12 cell lines measured with
quantitative RT-PCR assay.
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cancers. The predicted RB-negative frequencies deter-
mined by the cut-off value of log10 (CCND1/CDKN2A)
of 0.404 were 100% (7/7), 22% (2/9), 100% (5/5), and 5%
(1/20) in cervical, endometrial, small cell lung, and
gastric cancers, respectively (Table 2). All the normal
samples from the four tissues were predicted to be
RB-positive (100%) by the cut-off value. Since measuring
RB1 expression is a current standard method to deter-
mine RB1 status in clinical samples, we analyzed RB1 and
CCND1/CDKN2A mRNA expression levels in 6 SCLC
and 17 normal lung samples using publicly available
microarray data (Additional file 3). The CCND1/
CDKN2A ratio was significantly lower in all the SCLC
samples compared with normal lung samples, which is in
accordance with our data.
Discussion
Deregulation of RB1 has been reported in multiple types
of tumors, including retinoblastoma, cervical cancer, and
SCLC. Development of anti-tumor agents which selec-
tively kill RB1-negative tumors is expected to increase
the therapeutic window for treatment of tumors with an
RB1-negative background. Hence, various researchers are
trying to develop novel anti-tumor agents with selective
anti-tumor effects on RB1-deficient tumors [20,22,24], or
find RB1 context specificity for current standard-of-care
medicines [23,24]. Examples include the studies of topoi-
somerase inhibitors or ECT2 inhibition which are more
effective in RB1-negative tumors compared with RB1-
positive counterparts [20,21]. Since topoisomerases or
ECT2 are regulated by E2F transcription factors as down-
stream effectors of RB1, it is reasonable that their inhibi-
tions are sensitive to RB1-negative tumors. In order to
apply the information of the RB1 context specificity to
clinical trials, it is necessary to develop a classifier of RB1
status of clinical samples. The CCND1/CDKN2A assay
as a predictive biomarker for RB1 demonstrated in the
present study has several advantages. First, the assay
showed 100% prediction accuracy in the original 30 can-
cer cell lines determined by microarray, and 12 cultured
cell lines and four xenograft tumors determined by quan-
titative qPCR. The prevalence of RB1 deficiency in clini-
cal tumor and normal samples were also consistent with
previous reports using IHC for RB1. Second, the assay
provides quantitative and reproducible data when deter-
mined by RT-PCR with defined primer and probe
sequences. Therefore, the cut-off value to discriminate
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Figure 4 CCND1/CDKN2A expression predicts RB1 status in animal tumor models. (A) mRNAs from five xenograft tumors were purified
from FFPET and analyzed with quantitative RT-PCR for CCND1 and CDKN2A. NCI-H358, NCI-H441, and HCT116 cell lines are known to be RB1-
positve. HeLaS3 and H1048 cell lines are known to be RB1-negative. The cut-off value of log10 (CCND1/CDKN2A) ratio to classify RB1 status is
shown: 0.404. (B) CCND1/CDKN2A expression was analyzed in osteoblast cells derived from RB1 wild-type and RB1 knockout mice using publicly
available microarray expression data (GEO: GSE19299).
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Page 6 of 11RB1-positive and -negative cell lines by discriminant ana-
lysis could be established, while criteria to determine RB1
prevalence by conventional IHC-based assays is relatively
arbitrary. Third, although RB1 protein can be expressed
as an inactive form when tumor cells harbour missense
mutation in RB1 gene or HPV-mediated RB1 inactivation
which makes it difficult for IHC to classify RB1 func-
tional status, the CCND1/CDKN2A ratio expression
assay could detect various types of RB1 functional inacti-
vation as shown in Figure 1 and 2. Finally, the RT-PCR
assay requires a smaller amount of biopsy specimen.
Recent advances in RNA/cDNA amplification might
enable investigators to conduct the assay with less than
10 cells, in contrast to IHC which mandates several slices
of FFPET with good morphological integrity.
An inverse correlation of CDKN2A and RB1 expres-
sions has been reported in several types of cancers
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Figure 5 CCND1/CDKN2A expression in clinical tumor and normal tissues. FFPETs of clinical samples were obtained from the Kanagawa
Cancer Research and information Association. mRNAs from normal and tumor tissues were purified and analyzed with quantitative RT-PCR for
CCND1 and CDKN2A. The tissue type is designated in each figure; (A) cervical, (B) endometrial, (C) small cell lung, (D) stomach cancers and
corresponding normal tissues. The cut-off value of log10 (CCND1/CDKN2A) ratio to classify RB1 status is shown: 0.404.
Table 2 RB1-negative frequency in clinical samples
determined by the CCND1/CDKN2A expression ratio
Tissue Cervical Endometrial SCLC Stomach
Normal 0% (0/5) 0% (0/7) 0% 0% (0/13)
Tumor 100% (7/7) 22% (2/9) 100% (5/5) 5% (1/20)
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Page 7 of 11[12,13]. In cervical cancers infected with HPV, the func-
tion of RB1 is lost due to association with the E7 onco-
protein. Cervical cancers express high levels of
CDKN2A probably by a feedback mechanism [14]. An
anti-correlation of RB1 and CDKN2A expression was
also reported in SCLC, gastric cancer, oral cavity squa-
mous carcinoma or urinary bladder cancer [13,29-31].
In our experiments, the expression levels of both
CDKN2A and CCND1 were negatively and positively
correlated with RB1 status in accordance with previous
reports; however, neither accurately classified the status
of RB1 as demonstrated in Figure 2A. By combining the
expressions of CCND1 and CDKN2A, the prediction
accuracy was significantly increased to 100% in all 30
samples in the microarray, and in an additional study
with 12 cell lines in RT-PCR analysis.
Numerous studies with expression profiles have
reported gene signatures which are differentially
expressed between RB1-positive and -negative cells
[32-35]. Markey et al. found that more than 200 genes
are decreased by the induction of a mutated RB1 that is
refractory to CDK-mediated phosphorylation [32]. The
function of the gene signature is related to cell cycle
control, DNA repair, or chromatin control, consistent
with the well-established role of RB1. Semizarov et al.
reported another set of genes that are commonly
deregulated by several different sequences of siRNA for
RB1 [33]. Pathway analysis of the gene set by GeneMapp
and MappFinder software packages found that cellular
processes involved in DNA replication, mitotic cell
cycle, and chromosome maintenance were statistically
condensed in the gene set. These pioneering works ana-
lyzing global expression profiling of genetically engi-
neered RB1 loss highlighted the downstream effectors,
which are responsible for the function of RB1 to control
cell cycle or tumorigenesis. We tested whether the pre-
viously reported RB1 regulated gene signatures could
classify the RB1-positve and -negative cell lines used in
the present study (Table 1); however, the signatures did
not distinguish the RB1 status of the cell lines (data not
shown). The present study provides an RB1 classifier
that distinguishes the status of RB1 in both cell lines
and clinical samples. Since expression profiling of natu-
rally occurring RB1-positive and -negative cell lines was
used to develop the signature followed by the narrow-
ing-down of genes with biological information, this may
have resulted in higher accuracy for predicting RB1 sta-
tus in additional cell lines and xenograft tumors.
The prevalence of RB1 (-) in clinical tumors and nor-
mal samples was reasonable compared with previous
reports using IHC. While several reports have shown
that loss of RB1 is found in more than 90% of clinical
SCLCs [12], 100% (5/5) of SCLC samples examined here
were RB1-negative when classified by the CCND1/
CDKN2A expression assay. The reported RB1 loss
frequency of uterine cervical cancers and uterine endome-
trial cancers is more than 90% [14,15] and 3-6% [36,37],
respectively. Our assay showed 100% (7/7) and 22% (2/9)
for cervical and endometrial cancers, respectively. The
prevalence of RB1 (-) in previous studies of gastric cancers
using IHC for RB1 is relatively variable, ranging from
0-40% [27,28,38,39] depending on the different criteria
used among the studies. The CCND1/CDKN2A assay pre-
dicted 5% (1/20) as RB1 (-) cancers. In general, the fre-
quency of RB1 loss is highly correlated between previous
reports and the present study, and the data imply that the
CCND1/CDKN2A assay could be utilized to predict RB1
status clinically as a quantitative assay.
Development of predictive biomarkers is of great sig-
nificance for anti-tumor agents, since the response rate
is relatively lower compared with other diseases. In
order to develop a clinically available gene signature as
a biomarker, it is preferable to develop a biomarker
composed of a minimal number of genes [40]. Although
microarray technology allows us to measure genome-
wide expression profiles without limiting the number of
genes, it would be difficult to use the platform to stratify
patients in a clinical setting from the viewpoints of cost
performance and assay turn-over. A quantitative RT-
PCR-based method with two genes would be feasible for
conventional clinical trials. Additionally, a PCR-based
method to measure the status of RB1 as a biomarker
might be developed as an in vitro diagnostic (IVD),
since some IVDs utilize PCR to detect biomarkers such
as Ras, EGFR mutation, or HIV infection [41,42].
Conclusions
The present study identified that the expression ratio of
CCND1/CDKN2A predicts the status of RB1 in both
cultured cancer cell lines and clinical tumor samples.
Since many studies have been attempting to find cur-
rently available or novel anti-tumor agents which are
selectively effective for tumors with dysfunctional RB1,
the CCND1/CDKN2A ratio expression assay might con-
tribute to patient stratification as a highly accurate,
quantitative, and less invasive biomarker.
Methods
Cell lines and RB1 functional assay
Cell lines used to detect RB1 status listed in Table 1
were obtained from the American Type Culture Collec-
tion (ATCC), and were cultured according to the suppli-
er’s instructions. The RB1 functional status of each cell
line was determined by measuring the activity of the
E2F-regulatory reporter gene in response to CDKN2A
induction [20]. Cells in 6-well plates were co-transfected
with 100 ng of CDKN2A expression plasmid [20], 100
ng of luciferase reporter plasmid (pGL3-SV40, Promega,
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ciency, and 100 ng of SEAP reporter plasmid containing
t h eE 2 F - r e s p o n s i v ee l e m e n t ,p S E A P 2 - C D C 6[ 2 0 ]b ya
lipofection method using FuGENE6 (Roche Diagnostics,
Mannheim, Germany). At 48 hr post transfection, SEAP
activity was measured with a Reporter Assay Kit-SEAP
(Tokyo, Osaka, Japan). The SEAP activity was normal-
ized to luciferase activity. RB1 mutation information of
cell lines were obtained from the literature (Table 1)
and from the COSMIC database at Sanger Center (URL:
http://www.sanger.ac.uk/genetics/CGP/cosmic/).
Expression profiling of cell lines
Total RNAs were extracted from cells growing in log
phase using an RNeasy Kit (QIAGEN, Valentia, CA),
and were subjected to mRNA profiling using custom
Human 3.0 A1 arrays (Agilent Technologies, Santa
Clara, California) as directed by the manufacturer’s pro-
tocol. As a common reference sample for all cell lines,
Human Universal Reference RNA (Stratagene, La Jolla,
CA) was used. Scanned data were processed by Resolver
(Rosetta Biosoftware, Seattle, WA) to calculate the ratios
and p-values based on an error-weighted model for each
probe. For statistical analysis, R (GNU freeware) and
MATLAB (MathWorks Inc., Natick, MA) were used. To
identify genes whose expressions were correlated with
RB1 status, we first filtered out genes whose standard
deviation of log ratio values were less than 0.1 to
exclude genes with poor expression changes among cell
lines, and selected 194 genes whose expression levels
showed a p-value of 0.001 or less for Pearson correlation
coefficient with RB1 status (1 for RB1 positive, 0 for
RB1 negative).
Quantitative RT-PCR analysis
cDNA was synthesized from 1 μg of total RNA by using
TaqMan reverse transcription reagents (PE Applied Bio-
systems, #N8080234). Quantitative real-time PCR assays
for human CCND1, CDKN2A and RB1 were performed
in triplicate for cDNA samples in 384-well optical plates.
Data were collected and analyzed using an ABI PRISM
7900 sequence detector system (Applied Biosystems,
Foster City, CA). Pre-designed TaqMan probes and pri-
mers for CCND1 (Hs00277039_m1), CDKN2A
(Hs00233365_m1) and RB1 (Hs00153108_m1) genes
were purchased from Applied Biosystems, Inc. The
CCND1:CDKN2A ratio was calculated as follows:
Log10 (CCND1/CDKN2A) = (log10 ratio of CCND1 expression to that in HeLaS3)
−(log10 ratio of CDKN2A expression to that in HeLaS3).
For prediction of RB1 status, the log10 (CCND1/
CDKN2A) data of the test cell lines which include 7
RB1-positive and 5 RB1-negative lines were obtained by
the quantitative RT-PCR. Then, the following linear
discriminant function was derived: Y = 0.54 × log10
(CCND1/CDKN2A)-2.051094.
Then the functional RB1 status was determined as
follows:
Y > 0 (log10 (CCND1/CDKN2A) > 0.404), positive
functional RB1 status; and
Y < 0 (log10(CCND1/CDKN2A) < 0.404) negative
functional RB1 status.
Xenograft tumor samples
All animal studies were carried out in accordance with
good animal practices as defined by the Institutional
Animal Care and Use Committee (IACUC). Tumor cells
(NCI-H353, NCI-H441, HCT116, HeLaS3, and
NCI-H1048) were inoculated in the hind flank of immu-
nodeficient nude rats (F344/NJcl-rnu, CLEA Japan) as a
suspension in Matrigel (BD Bioscience, San Jose, CA).
After 1-2 weeks, xenograft tumors were collected and
stored as FFPETs. Extraction of RNA from normal and
tumor FFPET samples was carried out using FFPE-
RNeasy kit (QIAGEN). The purified RNA was subjected
to CCND1/CDKN2A expression analysis.
Clinical human tumors and normal tissues
Cervical, endometrial, gastric, small cell lung cancers
and corresponding normal tissue samples with informed
consent were obtained from Kanagawa Cancer Research
and Information Association (Kanagawa, Japan). Indivi-
dual institutional ethical committees approved the use
of all clinical materials. FFPET of the tumors were used
for RNA purification. First, normal tissues were dis-
sected and collected from a section of FFPET if the sec-
tion contained enough normal tissue. The tumor
samples contained small amount of normal samples by
the macro-dissection. Extraction of RNA from the nor-
mal and tumor FFPET samples was carried out using a
FFPE-RNeasy kit (QIAGEN). The purified RNA was
subjected to CCND1/CDKN2A expression analysis.
Microarray analysis of public data
Expression profiling data for mouse osteoblast cells
derived from both RB1 wild-type and RB1 deficient
mice were retrieved from the NCBI Gene Expression
Omnibus (GEO: GSE19299). Expression profiling data
for RB1-expressing and RB1-deficient SAOS-2 paired
cell lines were also retrieved from the NCBI GEO
(GSE9690). Expression profiling data of SCLC and nor-
mal lung samples were retrieved from Broad Institute
website http://www.broadinstitute.org/mpr/lung/.
The signal intensities of the probe sets were normalized
using the RMA method, and log ratio values to the aver-
age of all of the samples were calculated. The log10
(CCDN1/CDKN2A) value was then calculated for
each data.
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Additional file 1: RB1 status of 30 cell lines determined by RB1
functional assay. (A) Each cell line was transfected with E2F-regulatory
reporter SEAP plasmid with or without the CDKN2A expression vector.
The inhibition level of the SEAP reporter gene activity in response to
CDKN2A induction was normalized to luciferase activity. (B) RB1 mRNA
expression level measured by microarray. Relative mRNA expressions of
30 cell lines were shown as log10 ratio to HeLaS3 cells. Black bar:
functionally RB-positive cells; gray bar: functionally RB-negative cells.
Additional file 2: CCND1/CDKN2A expression distinguishes RB1-
expressing and RB1-deficient SAOS-2 cells. CCND1/CDKN2A
expression ratio was analyzed in both RB1-expressing and RB1-deficient
SAOS-2 cells using publicly available microarray expression profiling data
(GEO: GSE9690).
Additional file 3: CCND1/CDKN2A expression in clinical tumor and
normal tissues. CCND1/CDKN2A expression ratio (A) and RB1 expression
(B) in SCLC and normal lung samples were analyzed using publicly
available tumor microarray data that was retrieved from online
supplement data at http://www.genome.wi.mit.edu/MPR/lung.
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